An insight into GPCR and G-proteins as cancer drivers

PK Chaudhary, S Kim - Cells, 2021 - mdpi.com
G-protein-coupled receptors (GPCRs) are the largest family of cell surface signaling
receptors known to play a crucial role in various physiological functions, including tumor …

The renin–angiotensin system and cancer: old dog, new tricks

AJ George, WG Thomas, RD Hannan - Nature Reviews Cancer, 2010 - nature.com
For cancers to develop, sustain and spread, the appropriation of key homeostatic
physiological systems that influence cell growth, migration and death, as well as …

Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels

VP Chauhan, JD Martin, H Liu, DA Lacorre… - Nature …, 2013 - nature.com
Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour
blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to …

Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors

B Diop-Frimpong, VP Chauhan, S Krane… - Proceedings of the …, 2011 - pnas.org
The dense collagen network in tumors significantly reduces the penetration and efficacy of
nanotherapeutics. We tested whether losartan—a clinically approved angiotensin II receptor …

Linking heart failure to cancer: background evidence and research perspectives

E Bertero, M Canepa, C Maack, P Ameri - Circulation, 2018 - ahajournals.org
Recent epidemiological analyses suggest that incident cancer may be more common
among patients with preexisting heart failure (HF) than in patients without HF. Arguments …

The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies

B Hassani, Z Attar, N Firouzabadi - Cancer Cell International, 2023 - Springer
The renin-angiotensin-aldosterone system (RAAS), is an old system with new fundamental
roles in cancer biology which influences cell growth, migration, death, and metastasis. RAAS …

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals

ARB Trialists Collaboration - Journal of hypertension, 2011 - journals.lww.com
Background Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor
blockers (ARBs) reduce cardiovascular disease (CVD) events, but a recent meta-analysis of …

Drug combination and repurposing for cancer therapy: The example of breast cancer

AS Correia, F Gärtner, N Vale - Heliyon, 2021 - cell.com
Cancer is a set of extremely complex diseases, which are increasingly prominent today, as it
affects and kills millions of people worldwide, being the subject of intense study both in its …

GENT: gene expression database of normal and tumor tissues

G Shin, TW Kang, S Yang, SJ Baek… - Cancer …, 2011 - journals.sagepub.com
Background Some oncogenes such as ERBB2 and EGFR are over-expressed in only a
subset of patients. Cancer outlier profile analysis is one of computational approaches to …

Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins

YK Chae, ME Valsecchi, J Kim, AL Bianchi… - Cancer …, 2011 - Taylor & Francis
Background: Epidemiologic and biochemical evidence suggest a role of statins and
angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) as …